Looking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2016 Dec 23

PMID 28003728

Citations 1

Authors

Swastik Agrawal

Affiliations

Soon will be listed here.

Citing Articles

methanolic extract triggers apoptosis in HepG2 cells.

Ponselvi Induja M, Ezhilarasan D, Ashok Vardhan N Avicenna J Phytomed. 2018; 8(6):504-512.

PMID: 30456198 PMC: 6235665.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S . A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. Oncologist. 2013; 18(4):379-80. PMC: 3639524. DOI: 10.1634/theoncologist.2012-0221. View

Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S . Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013; 31(32):4067-75. DOI: 10.1200/JCO.2012.45.8372. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Johnson P, Qin S, Park J, Poon R, Raoul J, Philip P . Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013; 31(28):3517-24. DOI: 10.1200/JCO.2012.48.4410. View

Wang J, Changchien C, Hu T, Lee C, Kee K, Lin C . The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer. 2008; 44(7):1000-6. DOI: 10.1016/j.ejca.2008.02.018. View

Bitzer M, Horger M, Giannini E, Ganten T, Worns M, Siveke J . Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. J Hepatol. 2016; 65(2):280-8. DOI: 10.1016/j.jhep.2016.02.043. View

Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M . Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65(5):938-943. DOI: 10.1016/j.jhep.2016.05.044. View

Mann D . Epigenetics in liver disease. Hepatology. 2014; 60(4):1418-25. PMC: 4258082. DOI: 10.1002/hep.27131. View

10.

Cainap C, Qin S, Huang W, Chung I, Pan H, Cheng Y . Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2014; 33(2):172-9. PMC: 4279237. DOI: 10.1200/JCO.2013.54.3298. View

11.

Zhong J, Rodriguez A, Ke Y, Wang Y, Wang L, Li L . Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore). 2015; 94(3):e396. PMC: 4602643. DOI: 10.1097/MD.0000000000000396. View

12.

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

13.

Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View